Press Release:
biz.yahoo.com
Wednesday August 4, 8:31 am Eastern Time
Company Press Release
SOURCE: BioMarin Pharmaceutical Inc.
BioMarin Announces the Appointment of John L. Jost,
Ph.D. as Vice President Manufacturing
NOVATO, Calif., Aug. 4 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN;
SWX) announced the appointment of John L. Jost, Ph.D., as Vice President Manufacturing.
Dr. Jost joins BioMarin after fourteen years of progressively more responsible assignments in
manufacturing and process development at Genentech, Inc. and, before that, eleven years as a
research scientist in process development at The Upjohn Company. Dr. Jost's most recent
position at Genentech was Director of Manufacturing Sciences, where he started and managed
a department responsible for process monitoring, trouble- shooting and process improvements
for all the licensed products at Genentech. Before that assignment, Dr. Jost was Director of
Fermentation Research and Development at Genentech. Dr. Jost holds a Ph.D. in Chemical
Engineering from the University of Minnesota.
Grant W. Denison, Jr., Chairman and Chief Executive Officer of BioMarin, stated, ''We are
very pleased to have a manufacturing executive with John's extensive experience and record of
achievement join our BioMarin team. John's leadership of our manufacturing activities will be
essential to the achievement of our overall corporate objectives in the next three years. During
that time, we intend to develop the initial manufacturing operations and capabilities necessary
to produce the biopharmaceuticals needed for our lead product programs.''
BioMarin Pharmaceutical Inc. specializes in the discovery, development and commercialization
of carbohydrate enzyme therapeutics. Since inception in 1997, BioMarin has applied its
proprietary enzyme technology to the development of products in five therapeutic areas:
genetic diseases, burn debridement, fungal infections, pro-fertility, and inflammation (psoriasis).
Glyko, Inc., a BioMarin subsidiary, provides analytical and diagnostic services in the area of
carbohydrate biology.
This press release contains forward-looking statements about the business prospects of
BioMarin Pharmaceutical Inc. including the timing of manufacturing operations and capabilities
to support lead product programs. Results may differ materially depending on the progress of
BioMarin's product programs, availability of capital, future actions in the pharmaceutical
market and developments by competitors.
Regards,
TOPSTOCK |
